Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Sees Significant Growth in Short Interest

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the target of a large increase in short interest in July. As of July 15th, there was short interest totaling 1,161 shares, an increase of 57,950.0% from the June 30th total of 2 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 3,040 shares, the short-interest ratio is currently 0.4 days.

Enzon Pharmaceuticals Price Performance

Enzon Pharmaceuticals stock opened at $4.35 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16. Enzon Pharmaceuticals has a 1-year low of $1.50 and a 1-year high of $9.50. The company has a market cap of $3.22 million, a PE ratio of -0.64 and a beta of -0.05. The stock’s 50 day moving average price is $5.19 and its 200 day moving average price is $5.71.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last released its quarterly earnings data on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $86.54 million during the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.